A smiling child making a snow angel. The words "Prescribe More Time" are shown to the side.
Actor portrayal

The first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D)

in adult and pediatric patients aged 8 years and older with Stage 2 T1D.1 See patient selection criteria.

A smiling boy in swimwear with swim accessories next to the words, "Targets an underlying cause of T1D, not the symptoms!"
Actor portrayal

The first and only disease-modifying treatment in T1D

TZIELD is a CD3-directed monoclonal antibody that delays the onset of Stage 3 T1D.1

Two girls in pajamas, smiling and holding pillows during a pillow fight. They are next to the words, "See what's possible!"
Actor portrayal

TZIELD has been shown to delay Stage 3 T1D

In a clinical trial, TZIELD delayed the onset of Stage 3 T1D when compared with placebo.1

A girl looking determined wearing a baseball uniform and holding a baseball bat. She is next to the words "Ready for TZIELD!"
Actor portrayal

Ready to prescribe TZIELD?

Access information and resources about enrollment and patient support.



TZIELD is a CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.



  • Cytokine Release Syndrome (CRS): CRS occurred in TZIELD-treated patients during the treatment period and through 28 days after the last drug administration. Prior to TZIELD treatment, premedicate with antipyretics, antihistamines and/or antiemetics, and treat similarly if symptoms occur during treatment. If severe CRS develops, consider pausing dosing for 1 day to 2 days and administering the remaining doses to complete the full 14-day course on consecutive days; or discontinue treatment. Monitor liver enzymes during treatment. Discontinue TZIELD treatment in patients who develop elevated alanine aminotransferase or aspartate aminotransferase more than 5 times the upper limit of normal (ULN) or bilirubin more than 3 times ULN.
  • Serious Infections: Use of TZIELD is not recommended in patients with active serious infection or chronic infection other than localized skin infections. Monitor patients for signs and symptoms of infection during and after TZIELD administration. If serious infection develops, treat appropriately, and discontinue TZIELD.
  • Lymphopenia: Lymphopenia occurred in most TZIELD-treated patients. For most patients, lymphocyte levels began to recover after the fifth day of treatment and returned to pretreatment values within two weeks after treatment completion and without dose interruption. Monitor white blood cell counts during the treatment period. If prolonged severe lymphopenia develops (<500 cells per mcL lasting 1 week or longer), discontinue TZIELD.
1. TZIELD Prescribing Information. Provention Bio, Inc.